Nov 18 (Reuters) - Contineum Therapeutics Inc :
* CONTINEUM THERAPEUTICS EXPANDS CLINICAL DEVELOPMENT OF PIPE-791 WITH FDA AUTHORIZATION OF ITS INVESTIGATIONAL NEW DRUG $(IND.AU)$ APPLICATION FOR CHRONIC PAIN
* CONTINEUM THERAPEUTICS INC: PHASE 1B STUDY FOR POTENTIAL TREATMENT OF OSTEOARTHRITIS AND LOW BACK PAIN EXPECTED TO COMMENCE IN Q1 OF 2025
* CONTINEUM THERAPEUTICS INC - PHASE 1B STUDY FOR PIPE-791 TO BEGIN IN Q1 2025
* CONTINEUM THERAPEUTICS INC - TOPLINE DATA FROM PIPE-791 STUDY EXPECTED IN EARLY 2026
* CONTINEUM THERAPEUTICS INC - EXPECTS $213.9 MILLION CASH TO FUND OPERATIONS THROUGH 2027
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。